Axsome Therapeutics Book Value Per Share Growth & History (AXSM)
Axsome Therapeutics's book value per share was $1.74 for fiscal 2025.
View full Axsome Therapeutics company overviewAxsome Therapeutics annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.74 | $0.56 | +48.12% |
| 2024 | 2024-12-31 | $1.17 | -$2.86 | −70.95% |
| 2023 | 2023-12-31 | $4.03 | $1.51 | +60.14% |
| 2022 | 2022-12-31 | $2.52 | $2.11 | +509.34% |
| 2021 | 2021-12-31 | $0.41 | -$2.63 | −86.42% |
| 2020 | 2020-12-31 | $3.04 | -$1.79 | −37.08% |
| 2019 | 2019-12-31 | $4.84 | $4.81 | +15423.07% |
| 2018 | 2018-12-31 | $0.03 | -$0.62 | −95.25% |
| 2017 | 2017-12-31 | $0.66 | -$0.47 | −41.79% |
| 2016 | 2016-12-31 | $1.13 | -$1.30 | −53.55% |
| 2015 | 2015-12-31 | $2.43 | $2.78 | — |
| 2014 | 2014-12-31 | -$0.35 | — | — |
Axsome Therapeutics quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.59 | $0.13 | +8.58% |
| Q1 2026 | 2026-03-31 | $1.06 | -$0.02 | −1.80% |
| Q4 2025 | 2025-12-31 | $1.74 | $0.56 | +48.12% |
| Q3 2025 | 2025-09-30 | $1.47 | -$0.45 | −23.59% |
| Q2 2025 | 2025-06-30 | $1.47 | -$0.68 | −31.82% |
| Q1 2025 | 2025-03-31 | $1.08 | -$1.95 | −64.38% |
| Q4 2024 | 2024-12-31 | $1.17 | -$2.86 | −70.95% |
| Q3 2024 | 2024-09-30 | $1.92 | -$3.78 | −66.33% |
| Q2 2024 | 2024-06-30 | $2.15 | -$3.82 | −63.94% |
| Q1 2024 | 2024-03-31 | $3.03 | $0.47 | +18.19% |
| Q4 2023 | 2023-12-31 | $4.03 | $1.51 | +60.14% |
| Q3 2023 | 2023-09-30 | $5.70 | $2.07 | +57.18% |
| Q2 2023 | 2023-06-30 | $5.97 | $5.59 | +1466.92% |
| Q1 2023 | 2023-03-31 | $2.57 | $2.19 | +579.24% |
| Q4 2022 | 2022-12-31 | $2.52 | $2.11 | +509.34% |
| Q3 2022 | 2022-09-30 | $3.62 | $2.49 | +219.70% |
| Q2 2022 | 2022-06-30 | $0.38 | -$1.52 | −79.93% |
| Q1 2022 | 2022-03-31 | $0.38 | -$2.19 | −85.25% |
| Q4 2021 | 2021-12-31 | $0.41 | -$2.63 | −86.42% |
| Q3 2021 | 2021-09-30 | $1.13 | -$2.49 | −68.71% |
| Q2 2021 | 2021-06-30 | $1.90 | -$2.24 | −54.15% |
| Q1 2021 | 2021-03-31 | $2.56 | -$1.65 | −39.14% |
| Q4 2020 | 2020-12-31 | $3.04 | -$1.79 | −37.08% |
| Q3 2020 | 2020-09-30 | $3.62 | $3.43 | +1731.88% |
| Q2 2020 | 2020-06-30 | $4.14 | $3.43 | +485.13% |
| Q1 2020 | 2020-03-31 | $4.21 | $3.69 | +707.38% |
| Q4 2019 | 2019-12-31 | $4.84 | $4.81 | +15423.07% |
| Q3 2019 | 2019-09-30 | $0.20 | $0.17 | +604.52% |
| Q2 2019 | 2019-06-30 | $0.71 | $0.44 | +164.94% |
| Q1 2019 | 2019-03-31 | $0.52 | $0.03 | +5.90% |
| Q4 2018 | 2018-12-31 | $0.03 | -$0.62 | −95.25% |
| Q3 2018 | 2018-09-30 | $0.03 | -$0.68 | −96.05% |
| Q2 2018 | 2018-06-30 | $0.27 | -$0.70 | −72.30% |
| Q1 2018 | 2018-03-31 | $0.49 | -$0.75 | −60.39% |
| Q4 2017 | 2017-12-31 | $0.66 | -$0.47 | −41.79% |
| Q3 2017 | 2017-09-30 | $0.71 | -$0.76 | −51.64% |
| Q2 2017 | 2017-06-30 | $0.96 | -$0.86 | −47.12% |
| Q1 2017 | 2017-03-31 | $1.24 | -$0.91 | −42.24% |
| Q4 2016 | 2016-12-31 | $1.13 | -$1.30 | −53.55% |
| Q3 2016 | 2016-09-30 | $1.47 | — | — |
| Q2 2016 | 2016-06-30 | $1.82 | — | — |
| Q1 2016 | 2016-03-31 | $2.15 | — | — |
| Q4 2015 | 2015-12-31 | $2.43 | — | — |
Axsome Therapeutics book value per share trends
Over the last five fiscal years, Axsome Therapeutics's book value per share decreased from $3.04 to $1.74, a change of -$1.31. The latest reported quarter, Q2 2026, shows $1.59.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Axsome Therapeutics source filings ↗